CASI - CASI Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

CASI Pharmaceuticals, Inc.

9620 Medical Center Drive
Suite 300
Rockville, MD 20850
United States
240-864-2600
http://www.casipharmaceuticals.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees124

Key Executives

NameTitlePayExercisedYear Born
Dr. Wei-Wu HeChairman & CEO1.44MN/A1965
Dr. Wei Zhang Ph.D.Pres345.1kN/A1959
Mr. George Chi C.F.A., CPAChief Financial Officer300.06kN/A1969
Ms. Cynthia Wong HuCOO, Gen. Counsel & Sec.N/AN/A1970
Ms. Sara B. CapitelliVP of Fin. & Principal Accounting OfficerN/AN/A1966
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The company's product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkin's lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. In addition, the company engages in the development of a portfolio of 26 FDA-approved abbreviated new drug applications (ANDAs), including entecavir and tenofovir disoproxil fumarate indicated for hepatitis B virus; and 4 pipeline ANDAs that are pending FDA approval. Further, it is involved in developing ENMD-2076, an Aurora A/angiogenic kinase inhibitor that has completed Phase II studies for solid tumors, as well as various proprietary early-stage immune-oncological potential candidates in preclinical development. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.

Corporate Governance

CASI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.